Pure Red Cell Aplasia Overview

Save information for later
Sign Up

Learn About Pure Red Cell Aplasia

What is the definition of Pure Red Cell Aplasia?
Pure red cell aplasia (PRCA) is a rare condition that affects the bone marrow. Bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. In people with PRCA, the bone marrow makes a reduced number of red blood cells (called anemia). As a result, affected people may experience fatigue, lethargy, and pale skin. PRCA has many different causes. A rare congenital form of PRCA, called Diamond Blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. PRCA can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. In many cases, the cause of the condition is unknown (idiopathic).
What are the alternative names for Pure Red Cell Aplasia?
  • Pure red cell aplasia
  • PRCA
Who are the top Pure Red Cell Aplasia Local Doctors?
Kathleen M. Sakamoto
Elite in Pure Red Cell Aplasia
Dr. Kathleen M. Sakamoto
Pediatric Hematology Oncology | Pediatrics
Elite in Pure Red Cell Aplasia
Dr. Kathleen M. Sakamoto
Pediatric Hematology Oncology | Pediatrics
725 Welch Rd, 
Palo Alto, CA 
650-497-8000
Experience:
40+ years
Languages Spoken:
English

Kathleen Sakamoto is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Palo Alto, California. Dr. Sakamoto has been practicing medicine for over 40 years and is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, and Transient Erythroblastopenia of Childhood.

Jeffrey H. Lipton
Elite in Pure Red Cell Aplasia
Jeffrey H. Lipton
Elite in Pure Red Cell Aplasia
Jeffrey H. Lipton
55 Harbord St, M5S 2 W6, 
Toronto, ON, CA 

Jeffrey Lipton practices in Toronto, Canada. Lipton and is rated as an Elite expert by MediFind in the treatment of Pure Red Cell Aplasia. Their top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pure Red Cell Aplasia
Dr. Adrianna Vlachos
Pediatric Hematology Oncology
Elite in Pure Red Cell Aplasia
Dr. Adrianna Vlachos
Pediatric Hematology Oncology
601 5th St S, 
St Petersburg, FL 
727-767-3128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adrianna Vlachos is a Pediatric Hematologist Oncology provider in St Petersburg, Florida. Dr. Vlachos and is rated as an Elite provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, Transient Erythroblastopenia of Childhood, and Bone Marrow Transplant. Dr. Vlachos is currently accepting new patients.

View All Doctors
What are the latest Pure Red Cell Aplasia Clinical Trials?
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Enrollment Status: Recruiting
Publish Date: February 24, 2025

Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer. These cancer-...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.
A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia.
Enrollment Status: Recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Background: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Better treatments are needed.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center